MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA
Q1 2026 Positive Adjusted EBITDA(1) Net Revenue of $9M with strong gross margins of 37% OPEX decreased 28% in Q1 2026 versus Q4 2025 Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed productio…
This press release contains references to Adjusted EBITDA which is a non-IFRS financial measure. Management believes that this supplementary non-IFRS financial measure provides useful additional info…